Abstract
New halogenocadmate(II) complexes of the [CoLSX]2[CdX4] type containing the N-scorpionate ligand tris(1-(3,5-dimethylpyrazolylmethyl))amine (LS) were obtained in situ from a redox system using zerovalent cobalt as one of the substrates. The ligand tris(1-(3,5-dimethylpyrazolylmethyl)amine was synthesized in situ as a condensation product of 1-hydroxymethyl-3,5-dimethylpyrazole (L0) and an ammonia molecule formed during the redox process. Three complexes, namely, [CoLSCl]2[CdCl4]·CH3OH (1), [CoLSBr]2[CdBr4]·CH3OH (2) and [CoLSCl]2[CdCl4]·C7H8(3) were characterized by X-ray diffraction, IR, and UV–VIS analyses as well as magnetic and thermal investigations. The IR spectra were interpreted on the basis of theoretical (DFT) calculations and potential energy distribution (PED) analysis. Both the experimental and theoretical methods provided results that were reasonably compatible. For a comprehensive understanding of the complexes’ stability and their similarity with classical Trofimenko’s complexes, the cone angles were calculated.The anti-proliferative activity of the newly synthesized complexes was studied in vitro against selected human tumour cell lines (hepatocellular carcinoma Hep G2, lung carcinoma A549, colorectal adenocarcinomas SW480 and SW620) and normal human cells (fibroblasts). The cytotoxic evaluation revealed a high selectivity of complexes 1 and 2 towards cancer cells. The complexes were more active against tumour cells and less harmful towards normal cells than was the reference drug cisplatin.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call